Early iatrogenic menopause in gynecological cancer survivors and BRCA mutation (BRCAm) carriers undergoing risk-reducing salpingo-oophorectomy (RRSO) is a major health concern. Hormone replacement therapy (HRT) is the most effective remedy, but remains underused in clinical practice. The Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies (MITO) group promoted a national survey to investigate the knowledge and attitudes of healthcare professionals regarding the prescription of HRT.

中文翻译：

---

妇科癌症幸存者和 BRCA 突变携带者的激素替代疗法：MITO 小组调查。

接受降低风险输卵管卵巢切除术 (RRSO) 的妇科癌症幸存者和 BRCA 突变 (BRCAm) 携带者的早期医源性绝经是一个主要的健康问题。激素替代疗法（HRT）是最有效的治疗方法，但在临床实践中仍未得到充分利用。意大利卵巢癌和妇科恶性肿瘤多中心试验 (MITO) 小组推动了一项全国性调查，以调查医疗保健专业人员对 HRT 处方的知识和态度。